Sun Pharmaceutical Industries' Q2 FY 2025-26 Quarterly Results

Result Summary

• Sun Pharmaceutical Industries Ltd reported a 4.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 9.5%.
• Its expenses for the quarter were up by 4.4% QoQ and 7.3% YoY.
• The net profit increased 36.3% QoQ and increased 2.9% YoY.
• The earnings per share (EPS) of Sun Pharmaceutical Industries Ltd stood at 13 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Sun Pharmaceutical Industries Ltd is a leading pharmaceutical company based in India, known for its expertise in manufacturing and marketing a wide range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company is a significant player in the global generic drug market and has a robust portfolio that includes generics, branded generics, specialty products, and over-the-counter (OTC) products. Sun Pharma operates in various therapeutic segments such as cardiology, psychiatry, neurology, gastroenterology, and diabetology, among others. As of the latest data available, Sun Pharmaceutical Industries Ltd continues to strengthen its market position through strategic acquisitions and partnerships, which enhance its product offerings and market reach. Recent major developments include the company's focus on expanding its specialty product portfolio and increasing its presence in the U.S. market, which is a key region for its business.

Revenue

In the second quarter of fiscal year 2026 (Q2FY26), Sun Pharmaceutical Industries Ltd reported a total income of ₹14,948.23 crores, marking a 4.4% increase from the previous quarter (Q1FY26) where the total income was ₹14,315.86 crores. Comparing this to the same quarter in the previous year (Q2FY25), the company saw a year-over-year (YoY) growth of 9.5%, with total income previously reported at ₹13,645.39 crores. This consistent increase in total income reflects the company's continued expansion and growth in its operations. The revenue growth can be attributed to the company's broad product portfolio and its strategic efforts to enhance its market presence.

Profitability

For the quarter ending Q2FY26, Sun Pharmaceutical Industries Ltd's profit before tax was ₹4,167.61 crores, showing a significant quarter-over-quarter (QoQ) increase of 31.4% from ₹3,172.77 crores in Q1FY26. Compared to the same period last year (Q2FY25), the profit before tax increased by 15.8% from ₹3,597.88 crores. The profit after tax for Q2FY26 was ₹3,124.95 crores, marking a 36.3% QoQ rise from ₹2,292.87 crores in Q1FY26, and a 2.9% YoY increase from ₹3,037.33 crores in Q2FY25. These figures indicate a robust financial performance, with improved profitability metrics driven by efficient cost management and increased revenue. The reported earnings per share (EPS) for the quarter was ₹13.00, up from ₹9.50 in Q1FY26 and ₹12.70 in Q2FY25, reflecting a 36.8% QoQ increase and a 2.4% YoY rise.

Operating Metrics

The total expenses for Sun Pharmaceutical Industries Ltd in Q2FY26 were ₹10,780.62 crores, which represents a 4.4% increase from the previous quarter (Q1FY26) where expenses totaled ₹10,325.09 crores. On a year-over-year basis, total expenses increased by 7.3% from ₹10,047.51 crores in Q2FY25. The tax expense for Q2FY26 was ₹1,030.52 crores, up by 18.4% from ₹870.15 crores in Q1FY26, and a substantial 81.7% increase from ₹567.21 crores in Q2FY25. These operational figures underscore the company's ability to manage its expense structure effectively while maintaining growth in net income. The rise in tax expenses can be attributed to higher pre-tax profits, reflecting the overall improvement in profitability during the quarter.